Genetic testing resulted in diagnostic refinement with a potential change in clinical management in 8% of probands, according to Rafik Tadros, MD, PhD, of Montreal Heart Institute, and colleagues.

GENOMIC analysis of 11,555 congenital heart disease (CHD) probands identified 60 dominant genes contributing to 10.1% of ...

Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...

Sudden cardiac arrest (SCA) in healthy young individuals is a growing concern, with research from the NIH identifying key ...

With drugs on the horizon for treating and possibly preventing transthyretin amyloid cardiomyopathy, cardiologists are ...

A surprising mix of inherited and de novo mutations in 60 genes contribute to 10 percent of CHD cases. Many of these same ...

Genetic testing company 23andMe’s bankruptcy has led to a new consumer privacy issue: what happens to the DNA of millions of ...

based on cardiac magnetic resonance results. In addition to providing insight into the genetic determinants of the normal left ventricle's shape and function, additional light was shed on HCM's ...

Discover how the experimental drug lepodisiran dramatically lowers lipoprotein(a) levels, potentially transforming treatment ...

Studies conducted in human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) compared various cassette configurations and informed the final design of TN-201, which incorporates a ...